JP4380800B2 - マラリアの処置のための（＋）メフロキンの使用 - Google Patents

マラリアの処置のための（＋）メフロキンの使用 Download PDF

Info

Publication number
JP4380800B2
JP4380800B2 JP53828198A JP53828198A JP4380800B2 JP 4380800 B2 JP4380800 B2 JP 4380800B2 JP 53828198 A JP53828198 A JP 53828198A JP 53828198 A JP53828198 A JP 53828198A JP 4380800 B2 JP4380800 B2 JP 4380800B2
Authority
JP
Japan
Prior art keywords
composition
medical condition
subject
bis
piperidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP53828198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001526637A5 (enExample
JP2001526637A (ja
Inventor
フレッチャー，アラン
シェパード，ロビン
Original Assignee
バーナリス リサーチ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704809.4A external-priority patent/GB9704809D0/en
Priority claimed from GBGB9722232.7A external-priority patent/GB9722232D0/en
Priority claimed from GBGB9724263.0A external-priority patent/GB9724263D0/en
Priority claimed from GBGB9724712.6A external-priority patent/GB9724712D0/en
Application filed by バーナリス リサーチ リミテッド filed Critical バーナリス リサーチ リミテッド
Publication of JP2001526637A publication Critical patent/JP2001526637A/ja
Publication of JP2001526637A5 publication Critical patent/JP2001526637A5/ja
Application granted granted Critical
Publication of JP4380800B2 publication Critical patent/JP4380800B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP53828198A 1997-03-07 1998-03-06 マラリアの処置のための（＋）メフロキンの使用 Expired - Lifetime JP4380800B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9704809.4A GB9704809D0 (en) 1997-03-07 1997-03-07 Chemical compounds
GB9704809.4 1997-03-07
GB9722232.7 1997-10-21
GBGB9722232.7A GB9722232D0 (en) 1997-10-21 1997-10-21 Chemical compounds
GB9724263.0 1997-11-17
GBGB9724263.0A GB9724263D0 (en) 1997-11-17 1997-11-17 Chemical compounds
GBGB9724712.6A GB9724712D0 (en) 1997-11-21 1997-11-21 Chemical compounds
GB9724712.6 1997-11-21
PCT/GB1998/000675 WO1998039003A1 (en) 1997-03-07 1998-03-06 Use of (+)mefloquine for the treatment of malaria

Publications (3)

Publication Number Publication Date
JP2001526637A JP2001526637A (ja) 2001-12-18
JP2001526637A5 JP2001526637A5 (enExample) 2005-11-10
JP4380800B2 true JP4380800B2 (ja) 2009-12-09

Family

ID=27451612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53828198A Expired - Lifetime JP4380800B2 (ja) 1997-03-07 1998-03-06 マラリアの処置のための（＋）メフロキンの使用

Country Status (10)

Country Link
US (1) US6664397B1 (enExample)
EP (1) EP0966285B1 (enExample)
JP (1) JP4380800B2 (enExample)
AT (1) ATE225177T1 (enExample)
AU (1) AU730818B2 (enExample)
DE (1) DE69808440T2 (enExample)
DK (1) DK0966285T3 (enExample)
ES (1) ES2185153T3 (enExample)
PT (1) PT966285E (enExample)
WO (1) WO1998039003A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975345A1 (en) * 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
GB0021776D0 (en) 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
GB0406014D0 (en) * 2004-03-17 2004-04-21 Arakis Ltd Pharmaceutical composition and use
US20070032480A1 (en) * 2005-06-14 2007-02-08 The Johns Hopkins University Treatment of ischemia-induced arrhythmias
RU2008135762A (ru) * 2006-02-16 2010-03-27 Де МакЛин Хоспитал Корпорейшн (US) Способы и композиции для лечения болезни паркинсона
US20110039888A1 (en) * 2008-04-21 2011-02-17 Coltart Don M Asymmetric alpha functionalization and alpha, alpha bisfunctionalization of aldehydes and ketones
US8293783B2 (en) * 2009-03-24 2012-10-23 National University Of Singapore Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (COPD)
US8716265B2 (en) 2010-11-18 2014-05-06 Jenrin Discovery, Inc. 4-quinolinemethanols as anti-malarial agents
EP2487157A1 (en) 2011-02-11 2012-08-15 Université de Picardie Jules Verne Enantioselective synthesis method of 4-aminoalcoholquinoline derivatives and the use
RU2015105407A (ru) * 2012-08-09 2016-10-10 Кэн-Файт Биофарма Лтд. Лиганды аденозинового рецептора а3 для применения при лечении половой дисфункции
CN103304538B (zh) * 2013-06-21 2014-12-24 中国人民解放军第四军医大学 右旋甲氟喹的合成
CN107149601B (zh) * 2017-05-25 2020-04-17 中国中医科学院中药研究所 青蒿素类化合物在制备治疗神经病理性疼痛和/或并发症的药物中的应用
US11220482B2 (en) 2017-11-03 2022-01-11 Universite Amiens Picardie Jules Verne Aminopyridinemethanol compounds and their use
CN110507646A (zh) * 2019-09-12 2019-11-29 广州中医药大学(广州中医药研究院) 青蒿素衍生物在制备抗焦虑症的药物或缓解焦虑症的食品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2940443A1 (de) 1979-10-05 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von erythro-(alpha)-2-piperidyl-2,8-bis-(trifluormethyl)-4-chinolin-methanol
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system

Also Published As

Publication number Publication date
EP0966285B1 (en) 2002-10-02
EP0966285A1 (en) 1999-12-29
DK0966285T3 (da) 2002-10-28
ATE225177T1 (de) 2002-10-15
HK1024631A1 (en) 2000-10-20
ES2185153T3 (es) 2003-04-16
AU6506898A (en) 1998-09-22
US6664397B1 (en) 2003-12-16
DE69808440T2 (de) 2003-07-10
PT966285E (pt) 2002-12-31
AU730818B2 (en) 2001-03-15
DE69808440D1 (de) 2002-11-07
JP2001526637A (ja) 2001-12-18
WO1998039003A1 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
JP4380800B2 (ja) マラリアの処置のための（＋）メフロキンの使用
JP4934048B2 (ja) カンナビノイドの新規用途
HU202108B (en) Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
JP6659681B2 (ja) 不眠症を治療するための組成物および方法
CA2568218A1 (en) Multiple agent therapy for sexual dysfunction
KR101477043B1 (ko) 디스키네시아의 치료 또는 예방제
JP5148478B2 (ja) マラリア治療用のフェロキンとアーテミシニン誘導体との組合せ
EP3500268A1 (en) Ppary agonist for treatment of blood cancers
DE60132484T2 (de) Chinazolinderivate und -arzneimittel
CN101808646A (zh) 用于改善帕金森氏病的运动并发症或精神症状的药剂
CA2559282A1 (en) Methods for the treatment of synucleinopathies
JP5469707B2 (ja) 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物
KR19990036248A (ko) 마약성 진통제의 의존·내성 형성 억제제
JP7601458B2 (ja) スフィンゴシン－１－リン酸受容体アゴニストの使用
JPH0672098B2 (ja) コカイン、アンフェタミンおよびフェンシクリジン拮抗物質としての徐放性（強固結合性）ドーパミン、セロトニンまたはノルエピネフリン再取込阻害剤
CN100354274C (zh) 神经变性疾病的预防和治疗药物
EA010868B1 (ru) Применение производных бицикло[2.2.1]гептана для приготовления нейропротекторных фармацевтических композиций
HK1024631B (en) Use of (+) mefloquine for the treatment of malaria
JP2021504494A (ja) アデノシン誘導体を含む網膜疾患または視神経疾患の予防及び治療用薬学的組成物
TW568785B (en) Pharmaceutical composition for treating or preventing malaria in a subject with reduced side-effects
RU2850978C1 (ru) Применение агониста рецептора сфингозин-1-фосфата
CN1276753C (zh) 用于治疗类阿片依赖性的吡啶－2－基－甲胺衍生物
CA3037116A1 (en) Methods for treating ocular disease using inhibitors of csf-1r
JP2024156953A (ja) 認知症患者における行動・心理症状を治療するための方法
JP5020564B2 (ja) 薬剤耐性解除用の医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090401

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090605

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090825

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090915

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121002

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150